BR112018070350A2 - diagnóstico da ativação imunológica utilizando agentes de ligação a clever-1 tnf-alfa e hla-dr - Google Patents

diagnóstico da ativação imunológica utilizando agentes de ligação a clever-1 tnf-alfa e hla-dr

Info

Publication number
BR112018070350A2
BR112018070350A2 BR112018070350A BR112018070350A BR112018070350A2 BR 112018070350 A2 BR112018070350 A2 BR 112018070350A2 BR 112018070350 A BR112018070350 A BR 112018070350A BR 112018070350 A BR112018070350 A BR 112018070350A BR 112018070350 A2 BR112018070350 A2 BR 112018070350A2
Authority
BR
Brazil
Prior art keywords
macrophages
clever
hla
tnf
alpha
Prior art date
Application number
BR112018070350A
Other languages
English (en)
Inventor
Hollmén Maija-Leena
Jalkanen Markku
Maksimow Mikael
Viitala Miro
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of BR112018070350A2 publication Critical patent/BR112018070350A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

trata-se de um agente com capacidade de se ligar ao clever-1 em um indivíduo que pode ser usado na ativação de macrófagos para comutar o fenótipo dos mesmos de macrófagos m2 para macrófagos m1. a invenção se refere aos métodos para utilizar a capacidade dos macrófagos de comutar o fenótipo dos mesmos. em um aspecto, a invenção se refere a um método para estimativa da eficácia de terapia com anti-clever-1, monitorando-se uma modulação de macrófagos m2 para macrófagos m1, quando um agente com capacidade de se ligar ao clever-1 é administrado em um paciente, em que uma expressão de hla-dr ou secreção de tnf-alfa aumentada é indicativa de modulação de macrófagos m2 para macrófagos m1.
BR112018070350A 2016-04-18 2017-04-18 diagnóstico da ativação imunológica utilizando agentes de ligação a clever-1 tnf-alfa e hla-dr BR112018070350A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20165336 2016-04-18
PCT/FI2017/050286 WO2017182706A1 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents

Publications (1)

Publication Number Publication Date
BR112018070350A2 true BR112018070350A2 (pt) 2019-01-29

Family

ID=58692521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070350A BR112018070350A2 (pt) 2016-04-18 2017-04-18 diagnóstico da ativação imunológica utilizando agentes de ligação a clever-1 tnf-alfa e hla-dr

Country Status (10)

Country Link
US (1) US10884000B2 (pt)
EP (1) EP3445786B1 (pt)
JP (2) JP7100588B2 (pt)
KR (1) KR102403660B1 (pt)
CN (1) CN109153720B (pt)
AU (1) AU2017252344B2 (pt)
BR (1) BR112018070350A2 (pt)
CA (1) CA3020418A1 (pt)
EA (1) EA201892313A1 (pt)
WO (1) WO2017182706A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508049A (ja) 2018-11-01 2022-01-19 ファロン ファーマシューティカルズ オサケ ユキチュア 代替的に活性化されたマクロファージでのｃｌｅｖｅｒ－１発現のダウンレギュレーションに使用するためのｔｌｒ９アゴニスト
WO2021094652A1 (en) * 2019-11-11 2021-05-20 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
EP4139351A1 (en) * 2020-04-20 2023-03-01 Faron Pharmaceuticals OY Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
WO2023105118A1 (en) * 2021-12-07 2023-06-15 Faron Pharmaceuticals Oy Method for using inflammatory markers to guide anti-clever-1 cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4387797B2 (ja) * 2002-01-09 2009-12-24 ファロン ファーマシューティカルズ オサケ ユキチュア 共通リンパ管内皮および血管内皮受容体−１（ｃｌｅｖｅｒ−１）およびその用途
FI20090161A0 (fi) * 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
WO2014072441A1 (en) 2012-11-09 2014-05-15 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
DK3013350T3 (da) * 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser

Also Published As

Publication number Publication date
CA3020418A1 (en) 2017-10-26
KR102403660B1 (ko) 2022-05-30
US20190064180A1 (en) 2019-02-28
CN109153720B (zh) 2022-10-21
EP3445786C0 (en) 2023-10-04
AU2017252344A1 (en) 2018-10-11
JP7302049B2 (ja) 2023-07-03
EP3445786B1 (en) 2023-10-04
JP7100588B2 (ja) 2022-07-13
EA201892313A1 (ru) 2019-03-29
JP2019521312A (ja) 2019-07-25
AU2017252344B2 (en) 2023-12-21
EP3445786A1 (en) 2019-02-27
KR20180133854A (ko) 2018-12-17
JP2022065088A (ja) 2022-04-26
US10884000B2 (en) 2021-01-05
WO2017182706A1 (en) 2017-10-26
CN109153720A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
BR112018070350A2 (pt) diagnóstico da ativação imunológica utilizando agentes de ligação a clever-1 tnf-alfa e hla-dr
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
IL249330B (en) Pharmaceutical preparations for use in the prevention and/or treatment of a disease that develops or progresses as a result of a decrease or loss of factor viii blood clotting activity and/or activated blood clotting factor viii
BR112017003302A2 (pt) sal de adição de ácido do composto inibidor de trk
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112015029611A2 (pt) composições para uso em ruptura de cartilagem
IL282923A (en) Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
BR112016021648A2 (pt) novos compostos
BR112016018085A2 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
BR112015018827A2 (pt) composição farmacêutica oral para tratamento de mucosite oral e estomatite
BR112016025764A2 (pt) vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico
BR112017026241A2 (pt) composições farmacêuticas e alimentícias para induzir a saciação e prolongar a saciedade em indivíduos que necessitem das mesmas
GEP20186927B (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
CL2019000625A1 (es) Combinación de agonistas de fxr.
CL2019000914A1 (es) Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017016096A (es) Agente antihipertensivo.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]